title: Regression of vascular calcification in a patient treated with cinacalcet: a case report.
abstract: The purpose of this case report is to describe the regression of vascular calcifications (VC) in a patient with secondary hyperparathyroidism (SHPT) after having added cinacalcet to her treatment. We present the clinical case of a 48-year-old woman with chronic renal failure secondary to tubulointerstitial disease. She was being treated with long-term haemodialysis (HD) and underwent two kidney transplants with transplantectomies. The patient presented with severe SHPT caused by parathyroid gland hypertrophy. The radiology test showed signs of VC in the radial and interdigital arteries, and VC in a linear arrangement were observed in both breasts on the mammography. Cinacalcet was added to her treatment with vitamin D derivatives and phosphate-binding agents, which resulted in a good control of mineral metabolism. The radiology test showed that the calcification in the interdigital artery had disappeared and that the bone appeared to be more structured. The mammography also showed regression of the VC. To conclude, cinacalcet may have potential for regression of VC in patients with SHPT.
authors.affiliation: Nephrology Department, Virgen Macarena Hospital Area, Seville, Spain. msalgueira@yahoo.es
authors.forename: M
authors.initials: M
authors.lastname: Salgueira
authors.forename: A I
authors.initials: AI
authors.lastname: Martínez
authors.forename: J A
authors.initials: JA
authors.lastname: Milán
mesh_terms: D001940:Breast / Q000098:blood supply; D057966:Calcimimetic Agents / Q000627:therapeutic use*; D002117:Calcitriol / Q000627:therapeutic use; D002119:Calcium Carbonate / Q000627:therapeutic use; D002614:Chelating Agents / Q000627:therapeutic use; D000069449:Cinacalcet; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000601:surgery; D006225:Hand / Q000098:blood supply; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000601:surgery / Q000628:therapy; D016030:Kidney Transplantation; D008327:Mammography; D008875:Middle Aged; D009281:Naphthalenes / Q000627:therapeutic use*; D009395:Nephritis, Interstitial / Q000150:complications; D010758:Phosphorus; D011073:Polyamines / Q000627:therapeutic use; D006435:Renal Dialysis; D012086:Reoperation; D000069603:Sevelamer; D061205:Vascular Calcification / Q000000981:diagnostic imaging / Q000188:drug therapy*
chemical_list: D057966:Calcimimetic Agents; D002614:Chelating Agents; D006887:Hydroxycholecalciferols; D009281:Naphthalenes; D011073:Polyamines; D010758:Phosphorus; D000069603:Sevelamer; D002117:Calcitriol; D002119:Calcium Carbonate; D000069449:Cinacalcet; C008088:alfacalcidol